Abstract RNA N6-methyladenosine (m6A) modification occurs in approximately 25% of
mRNAs at the transcriptome-wide level. RNA m6A is regulated by the RNA m6A …

Abstract N6-methyladenosine (m 6 A) RNA methylation is the most abundant form of mRNA
modification in eukaryotes and is at the front line of biological and biomedical research. This …

Tumor immune microenvironment (TIME) regulators are promising cancer
immunotherapeutic targets. IGF2BP1, as a crucial N 6-methyladenosine (m6A) reader …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers. It
thrives in a malnourished environment; however, little is known about the mechanisms by …

Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant
cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological …

RNA modification has recently become a significant process of gene regulation, and the
methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification …

RNA binding proteins that act at the post-transcriptional level display a richness of
mechanisms to modulate the transcriptional output and respond to changing cellular …

Embryonic development is characterized by rapidly dividing cells, cellular plasticity and a
highly vascular microenvironment. These features are similar to those of tumour tissue, in …

The tumor microenvironment (TME), which is regulated by intrinsic oncogenic mechanisms
and epigenetic modifications, has become a research hotspot in recent years. Characteristic …

Abstract N 6-methyladenosine (m 6 A) is a prevalent internal modification in eukaryotic
RNAs regulated by the so-called “writers”,“erasers”, and “readers”. m 6 A has been …